A method for monitoring a liver pathology in a human subject, comprising the steps of: (a) determining a concentration of albumin mRNA in an acellular blood sample taken from a human subject at a first time; (b) determining a concentration of albumin mRNA in an acellular blood sample taken from a human subject at a second time; and comparing the concentration of albumin mRNA from step (a) with the concentration of albumin mRNA from step (b), (i) when the concentration of albumin mRNA from step (a) is higher than a standard control, wherein the concentration of albumin mRNA from step (b) being higher than the concentration of albumin mRNA from step (a) indicates a worsening of the liver pathology, and the concentration of albumin mRNA from step (b) being lower than the concentration of albumin mRNA from step (a) indicates an improvement of the liver pathology, and (ii) when the concentration of albumin mRNA from step (a) is substantially the same as the standard control, wherein the concentration of albumin mRNA from step (a) and step (b) being substantially unchanged indicates that the subject is free of the liver pathology, and wherein the concentration of albumin mRNA from step (b) being higher than the concentration of albumin mRNA from step (a) indicates the occurrence of a liver disease. (a) determining a concentration of albumin mRNA in an acellular blood sample taken from a human subject at a first time; (b) determining a concentration of albumin mRNA in an acellular blood sample taken from a human subject at a second time; and comparing the concentration of albumin mRNA from step (a) with the concentration of albumin mRNA from step (b), (i) when the concentration of albumin mRNA from step (a) is higher than a standard control, wherein the concentration of albumin mRNA from step (b) being higher than the concentration of albumin mRNA from step (a) indicates a worsening of the liver pathology, and the concentration of albumin mRNA from step (b) being lower than the concentration of albumin mRNA from step (a) indicates an improvement of the liver pathology, and (ii) when the concentration of albumin mRNA from step (a) is substantially the same as the standard control, wherein the concentration of albumin mRNA from step (a) and step (b) being substantially unchanged indicates that the subject is free of the liver pathology, and wherein the concentration of albumin mRNA from step (b) being higher than the concentration of albumin mRNA from step (a) indicates the occurrence of a liver disease. (i) when the concentration of albumin mRNA from step (a) is higher than a standard control, wherein the concentration of albumin mRNA from step (b) being higher than the concentration of albumin mRNA from step (a) indicates a worsening of the liver pathology, and the concentration of albumin mRNA from step (b) being lower than the concentration of albumin mRNA from step (a) indicates an improvement of the liver pathology, and (ii) when the concentration of albumin mRNA from step (a) is substantially the same as the standard control, wherein the concentration of albumin mRNA from step (a) and step (b) being substantially unchanged indicates that the subject is free of the liver pathology, and wherein the concentration of albumin mRNA from step (b) being higher than the concentration of albumin mRNA from step (a) indicates the occurrence of a liver disease. <EOS>